Scolaris Content Display Scolaris Content Display

Intervenciones para mejorar la adherencia al tratamiento de quelación del hierro en pacientes con anemia de células falciformes o talasemia

This is not the most recent version

Appendices

Appendix 1. Search strategies

The following databases will be searched using the strategies below (without study filters):

CENTRAL & DARE, (The Cochrane Library)
#1 MeSH descriptor: [Patient Acceptance of Health Care] explode all trees
#2 MeSH descriptor: [Patient Education as Topic] this term only
#3 MeSH descriptor: [Data Collection] explode all trees
#4 (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*):ti
#5 ((adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*) near/6 (patient* or treatment* or therapy or therapies or medication* or drug*)):ab
#6 (patient* near/3 (dropout* or drop* out*))
#7 MeSH descriptor: [Treatment Refusal] this term only
#8 (treatment* near/3 refus*)
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 MeSH descriptor: [Iron Chelating Agents] explode all trees
#11 MeSH descriptor: [Chelation Therapy] this term only
#12 (chelat* near/3 (treatment* or therap*))
#13 (deferoxamine* or deferoximine* or deferrioxamine* or desferioximine* or desferrioxamine* or desferroxamine* or desferal* or desferral* or DFO or desferin* or desferol* or dfom)
#14 (deferiprone or L1* or kelfer or DMHP or ferriprox or CP20 or dmohpo or hdmpp CPD or hdpp)
#15 (exjade* or deferasirox* or ICL 670* or icl670* or "CGP 72670")
#16 (iron near/5 (chelat* or reduc*))
#17 #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 MeSH descriptor: [Thalassemia] explode all trees
#19 (thalassemi* or thalassaemi* or lepore or hydrops fetalis)
#20 ((hemoglobin or haemoglobin) near/3 disease)
#21 (hemochromatosis or haemochromatosis or hemosiderosis or haemosiderosis)
#22 ((mediterranean or erythroblastic or cooley*) next (anemi* or anaemi*))
#23 MeSH descriptor: [Iron Overload] explode all trees
#24 (iron near/3 (overload* or over‐load*))
#25 MeSH descriptor: [Hemoglobinopathies] this term only
#26 MeSH descriptor: [Hemoglobin C Disease] this term only
#27 (hemoglobinopath* or haemoglobinopath*)
#28 MeSH descriptor: [Anemia, Sickle Cell] explode all trees
#29 (barts and (blood or plasma))
#30 (sickle cell or sicklemi* or sickled or sickling or meniscocyt* or drepanocyt*)
#31 (hemoglobin S or hemoglobin SC or hemoglobin SE or hemoglobin SS or hemoglobin C or hemoglobin D or
haemoglobin S or haemoglobin SC or haemoglobin SE or haemoglobin SS or haemoglobin C or haemoglobin D Hb S or Hb SC or Hb SE or Hb SS or Hb C or Hb D or SC disease)
#32 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31
#33 #9 and #17 and #32
#34 ((thalassemi* or thalassaemi* or sickle or hemoglobinopath* or haemoglobinopath*) and (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or educat*)):ti
#35 #33 or #34

PubMed (for Epub Ahead of Print, In‐Process & Other Non‐Indexed Citations only)
#1 ((adher* OR nonadher* OR complian* OR comply* OR noncomplian* OR noncomply* OR complier* OR noncomplier* OR accept* OR nonaccept* OR abandon* OR co‐operat* OR cooperat* OR unco‐operative* OR uncooperative* OR nonco‐operat* OR noncooperat* OR satisfaction OR dissatisfaction OR persist* OR educat* OR questionnaire*) AND (patient OR patients OR treatment* OR therapy OR therapies OR medication* OR drug*))
#2 (patient dropout* OR patient drop* outs OR patients drop* out OR treatment* refus* OR refus* treatment*)
#3 #1 OR #2
#4 (deferoxamine* OR deferoximine* OR deferrioxamine* OR desferioximine* OR desferrioxamine* OR desferroxamine* OR desferal* OR desferral* OR DFO OR desferin* OR desferol* OR dfom OR deferiprone OR L1 OR kelfer OR DMHP OR ferriprox OR CP20 OR dmohpo OR hdmpp CPD OR hdpp OR exjade* OR deferasirox* OR ICL 670* OR icl670* OR CGP "72670" OR iron chelat* OR iron reduc* OR chelat* treatment* OR chelat* therapy)
#5 (thalassemi* OR thalassaemi* OR lepore OR hydrops fetalis OR cooley* anemi* OR cooley* anaemi*)
#6 (hemoglobin disease OR haemoglobin disease OR hemochromatosis OR haemochromatosis OR hemosiderosis OR haemosiderosis)
#7 (mediterranean anemi* OR mediterranean anaemi* OR erythroblastic anemi* OR erythroblastic anaemi*)
#8 hemoglobinopath* OR haemoglobinopath* OR iron overload* OR iron over‐load*
#9 ("sickle cell" OR sicklemi* OR sickled OR sickling OR meniscocyt* OR drepanocyt* OR "hemoglobin S" OR "hemoglobin SC" OR "hemoglobin SE" OR "hemoglobin SS" OR "hemoglobin C" OR "hemoglobin D" OR "haemoglobin S" OR "haemoglobin SC" OR "haemoglobin SE" OR "haemoglobin SS" OR "haemoglobin C" OR "haemoglobin D" OR "Hb S" OR "Hb SC" OR "Hb SE" OR "Hb SS" OR "Hb C" OR "Hb D" OR "SC disease")
#10 #5 OR #6 OR #7 OR #8 OR #9
#11 #3 AND 4 AND #10
#12 ((adher*[TI] OR nonadher*[TI] OR complian*[TI] OR comply*[TI] OR noncomplian*[TI] OR noncomply*[TI] OR complier*[TI] OR noncomplier*[TI] OR accept*[TI] OR nonaccept*[TI] OR abandon*[TI] OR co‐operat*[TI] OR cooperat*[TI] OR unco‐operative*[TI] OR uncooperative*[TI] OR nonco‐operat*[TI] OR noncooperat*[TI] OR satisfaction[TI] OR dissatisfaction[TI] OR persist*[TI] OR educat*[TI] OR questionnaire*[TI]) AND (thalassemia*[TI] OR thalassaemia*[TI] OR sickle[TI] OR iron overload*[TI]))
#13 #11 OR #12
#14 (publisher[sb] OR inprocess[sb] OR pubmednotmedline[sb])
#15 #13 AND #14

MEDLINE (OvidSP)
1. exp "Patient Acceptance of Health Care"/
2. (px or ed).fs.
3. "Patient Education as Topic"/
4. exp Data Collection/
5. (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*).ti.
6. ((adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*) adj6 (patient* or treatment* or therapy or therapies or medication* or drug*)).ab,kf.
7. (patient* adj3 (dropout* or drop* out*)).tw,kf.
8. Treatment Refusal/
9. (treatment* adj3 refus*).tw,kf.
10. or/1‐9
11. exp IRON CHELATING AGENTS/
12. CHELATION THERAPY/
13. (chelation adj3 (treatment* or therap*)).tw,kf.
14. (deferoxamine* or deferoximine* or deferrioxamine* or desferioximine* or desferrioxamine* or desferroxamine* or desferal* or desferral* or DFO or desferin* or desferol* or dfom).mp.
15. (deferiprone or L1* or kelfer or DMHP or ferriprox or CP20 or dmohpo or hdmpp CPD or hdpp).mp.
16. (exjade* or deferasirox* or ICL 670* or icl670* or "CGP 72670").mp.
17. (iron adj5 (chelat* or reduc*)).tw,kf.
18. or/11‐17
19. exp THALASSEMIA/
20. (thalass?emi* or lepore or hydrops fetalis).tw,kf.
21. ((hemoglobin or haemoglobin) adj3 disease).tw,kf.
22. (hemochromatosis or haemochromatosis or hemosiderosis or haemosiderosis).tw,kf.
23. ((mediterranean or erythroblastic or cooley*) adj (anemi* or anaemi*)).tw,kf.
24. exp IRON OVERLOAD/
25. (iron adj3 (overload* or over‐load*)).tw,kf.
26. exp HEMOGLOBINOPATHIES/
27. exp HEMOGLOBIN, SICKLE/
28. (hemoglobinopath* or haemoglobinopath*).tw,kf.
29. exp ANEMIA, SICKLE CELL/
30. (barts and (blood or plasma)).tw,kf.
31. (sickle or sicklemi* or sickled or sickling or meniscocyt* or drepanocyt*).tw,kf.
32. (h?emoglobin s or h?emoglobin sc or h?emoglobin se or h?emoglobin ss or h?emoglobin c or h?emoglobin d or Hb s or Hb sc or Hb se or Hb ss or Hb c or Hb d or sc disease*).tw,kf.
33. or/19‐32
34. 10 and 18 and 33
35. exp *Hemoglobinopathies/ or (thalass?emi* or sickle or hemoglobinopath* or haemoglobinopath*).ti.
36. exp *Patient Compliance/ or (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or educat*).ti.
37. 35 and 36
38. 34 or 37

Embase (OvidSP)
1. exp THALASSEMIA/
2. (thalass?emi* or lepore or hydrops fetalis).tw,kf.
3. ((hemoglobin or haemoglobin) adj3 disease).tw,kf.
4. (hemochromatosis or haemochromatosis or hemosiderosis or haemosiderosis).tw,kf.
5. ((mediterranean or erythroblastic or cooley*) adj (anemi* or anaemi*)).tw,kf.
6. IRON OVERLOAD/
7. (iron adj3 (overload* or over‐load*)).tw,kf.
8. HEMOGLOBINOPATHY/
9. HEMOGLOBIN S/
10. (hemoglobinopath* or haemoglobinopath*).tw,kf.
11. exp SICKLE CELL ANEMIA/
12. (barts and (blood or plasma)).tw,kf.
13. (sickle or sicklemi* or sickled or sickling or meniscocyt* or drepanocyt*).tw,kf.
14. (h?emoglobin s or h?emoglobin sc or h?emoglobin se or h?emoglobin ss or h?emoglobin c or h?emoglobin d or Hb s or Hb sc or Hb se or Hb ss or Hb c or Hb d or sc disease*).tw,kf.
15. or/1‐14
16. exp PATIENT ATTITUDE/
17. PATIENT EDUCATION/
18. "PATIENT EDUCATION AS TOPIC"/
19. exp DATA COLLECTION METHOD/
20. (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*).ti.
21. ((adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*) adj6 (patient* or treatment* or therapy or therapies or medication* or drug*)).ab,kf.
22. (patient* adj3 (dropout* or drop* out*)).tw.
23. (treatment* adj3 refus*).tw.
24. or/16‐23
25. IRON CHELATING AGENT/
26. CHELATION THERAPY/
27. (chelation adj3 (treatment* or therap*)).tw,kf.
28. (deferoxamine* or deferoximine* or deferrioxamine* or desferioximine* or desferrioxamine* or desferroxamine* or desferal* or desferral* or DFO or desferin* or desferol* or dfom).mp.
29. (deferiprone or L1* or kelfer or DMHP or ferriprox or cp20 or dmohpo or hdmpp CPD or hdpp).mp.
30. (exjade* or deferasirox* or (icl adj 670*) or icl670* or (cgp adj "72670")).mp.
31. (iron adj5 (chelat* or reduc*)).tw.
32. or/25‐31
33. 15 and 24 and 32
34. exp *Hemoglobinopathy/ or (thalass?emi* or sickle or hemoglobinopath* or haemoglobinopath*).ti.
35. exp *Patient Compliance/ or (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or educat*).ti.
36. 34 and 35
37. 33 or 36

CINAHL (EBSCOHost)
S1 (MH "Patient Compliance+")
S2 (MH "Patient Education")
S3 (MH "Instrument by Type+")
S4 TI (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*)
S5 AB ((adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*) N6 (patient* or treatment* or therapy or therapies or medication* or drug*))
S6 TX (patient* N3 (dropout* or drop* out*))
S7 MH Treatment Refusal
S8 TX (treatment* N3 refus*)
9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8
S10 (MH "Chelating Agents+")
S11 (MH "Chelation Therapy")
S12 TX (deferoxamine* or deferoximine* or deferrioxamine* or desferioximine* or desferrioxamine* or desferroxamine* or desferal* or desferral* or DFO or desferin* or desferol* or dfom)
S13 TX (deferiprone or L1* or kelfer or DMHP or ferriprox or CP20 or dmohpo or hdmpp CPD or hdpp)
S14 TX (exjade* or deferasirox* or ICL 670* or icl670* or "CGP 72670")
S15 TX (iron N5 (chelat* or reduc*)) OR TX (chelat* N3 (treatment* or therap*))
S16 S10 OR S11 OR S12 OR S13 OR S14 OR S15
S17 (MH "Thalassemia+")
S18 TX (thalassemi* or thalassaemi* or lepore or hydrops fetalis)
S19 TX ((hemoglobin or haemoglobin) N3 disease)
S20 TX (hemochromatosis or haemochromatosis or hemosiderosis or haemosiderosis)
S21 TX ((mediterranean or erythroblastic or cooley*) N1 (anemi* or anaemi*))
S22 (MH "Iron Overload+")
S23 TX (iron N3 (overload* or over‐load*))
S24 (MH "Hemoglobinopathies")
S25 TX (hemoglobinopath* or haemoglobinopath*)
S26 (MH "Anemia, Sickle Cell+")
S27 TX (barts and (blood or plasma))
S28 TX (sickle OR sicklemi* OR sickled OR sickling OR meniscocyt* OR drepanocyt* OR "hemoglobin S" OR "hemoglobin SC" OR "hemoglobin SE" OR "hemoglobin SS" OR "hemoglobin C" OR "hemoglobin D" OR "haemoglobin S" OR "haemoglobin SC" OR "haemoglobin SE" OR "haemoglobin SS" OR "haemoglobin C" OR "haemoglobin D" OR "Hb S" OR "Hb SC" OR "Hb SE" OR "Hb SS" OR "Hb C" OR "Hb D" OR "SC disease")
S29 S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28
S30 S9 AND S16 AND S29
S31 (MM "Patient Compliance+")
S32 TI (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or educat*)
S33 S31 OR S32
S34 (MM "Hemoglobinopathies+")
S35 TI (thalassemi* or thalassaemi* or sickle or hemoglobinopath* or haemoglobinopath*)
S36 S34 OR S35
S37 S33 AND S36
S38 S30 OR S37

ProQuest Dissertations & Theses Global
ti(adher* OR nonadher* OR complian* OR comply* OR noncomplian* OR noncomply* OR complier* OR noncomplier* OR accept* OR nonaccept* OR abandon* OR co‐operat* OR cooperat* OR unco‐operative* OR uncooperative* OR nonco‐operat* OR noncooperat* OR satisfaction OR dissatisfaction OR refus* OR persist* OR educat* OR questionnaire*) AND ti(thalassemia OR thalassaemia OR sickle OR sickled OR sickling OR iron overload OR hemoglobinopath*) AND (chelation OR chelating OR deferiprone OR deferoxamine OR deferasirox OR DFO OR ferriprox OR exjade OR iron reduction)

PsycINFO (EBSCOHost) & Psychology and Behavioral Sciences Collection (EBSCOHost)
S1 DE "Treatment Compliance" OR DE "Compliance" OR DE "Treatment Refusal" OR DE "Treatment Dropouts" OR DE "Treatment Termination"
S2 DE "Client Education"
S3 DE "Questionnaires" OR DE "General Health Questionnaire"
S4 TI (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*)
S5 AB ((adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or abandon* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or persist* or educat* or questionnaire*) N6 (patient* or treatment* or therapy or therapies or medication* or drug*))
S6 TX (patient* N3 (dropout* or drop* out*))
S7 DE Treatment Refusal
S8 TX (treatment* N3 refus*)
S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8
S10 TX (deferoxamine* or deferoximine* or deferrioxamine* or desferioximine* or desferrioxamine* or desferroxamine* or desferal* or desferral* or DFO or desferin* or desferol* or dfom)
S11 TX (deferiprone or L1* or kelfer or DMHP or ferriprox or CP20 or dmohpo or hdmpp CPD or hdpp)
S12 TX (exjade* or deferasirox* or ICL 670* or icl670* or "CGP 72670")
S13 TX (iron N5 (chelat* or reduc*)) OR TX (chelat* N3 (treatment* or therap*))
S14 S10 OR S11 OR S12 OR S13
S15 TX (thalassemi* or thalassaemi* or lepore or hydrops fetalis)
S16 TX ((hemoglobin or haemoglobin) N3 disease)
S17 TX (hemochromatosis or haemochromatosis or hemosiderosis or haemosiderosis)
S18 TX ((mediterranean or erythroblastic or cooley*) N1 (anemi* or anaemi*))
S19 TX (iron N3 (overload* or over‐load*))
S20 TX (hemoglobinopath* or haemoglobinopath*)
S21 DE "Sickle Cell Disease"
S22 TX (barts and (blood or plasma))
S23 TX (sickle OR sicklemi* OR sickled OR sickling OR meniscocyt* OR drepanocyt* OR "hemoglobin S" OR
"hemoglobin SC" OR "hemoglobin SE" OR "hemoglobin SS" OR "hemoglobin C" OR "hemoglobin D" OR "haemoglobin S" OR "haemoglobin SC" OR "haemoglobin SE" OR "haemoglobin SS" OR "haemoglobin C" OR "haemoglobin D" OR "Hb S" OR "Hb SC" OR "Hb SE" OR "Hb SS" OR "Hb C" OR "Hb D" OR "SC disease")
S24 S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23
S25 S9 AND S14 AND S24
S26 MM "Treatment Compliance"
S27 TI (adher* or nonadher* or complian* or comply* or noncomplian* or noncomply* or complier* or noncomplier* or accept* or nonaccept* or co‐operat* or cooperat* or unco‐operative* or uncooperative* or nonco‐operat* or noncooperat* or satisfaction or dissatisfaction or educat*)
S28 S26 OR S27
S29 MM "Sickle Cell Disease"
S30 TI (thalassemi* or thalassaemi* or sickle or hemoglobinopath* or haemoglobinopath*)
31 S29 OR S30
S32 S28 AND S31
S33 S25 OR S32

Web of Science CPCI‐S & CPSSI
#1 TS=((adher* OR nonadher* OR complian* OR comply* OR noncomplian* OR noncomply* OR complier* OR noncomplier* OR accept* OR nonaccept* OR abandon* OR co‐operat* OR cooperat* OR unco‐operative* OR uncooperative* OR nonco‐operat* OR noncooperat* OR satisfaction OR dissatisfaction OR persist* OR educat* OR questionnaire*) AND (patient* OR treatment* OR therapy OR therapies OR medication* OR drug*))
#2 TS=(patient dropout* OR patient drop* outs OR patients drop* out OR treatment* refus* OR refus* treatment*)
#3 #1 OR #2
#4 TS=(deferoxamine* OR deferoximine* OR deferrioxamine* OR desferioximine* OR desferrioxamine* OR desferroxamine* OR desferal* OR desferral* OR DFO OR desferin* OR desferol* OR dfom OR deferiprone OR L1 OR kelfer OR DMHP OR ferriprox OR CP20 OR dmohpo OR hdmpp CPD OR hdpp OR exjade* OR deferasirox* OR ICL 670* OR icl670* OR CGP "72670" OR iron chelat* OR iron reduc* OR chelat* treatment* OR chelat* therap*)
#5 TS=(thalassemi* OR thalassaemi* OR lepore OR hydrops fetalis OR cooley* anemi* OR cooley* anaemi* OR hemoglobin disease OR haemoglobin disease OR hemochromatosis OR haemochromatosis OR hemosiderosis OR haemosiderosis OR mediterranean anemi* OR mediterranean anaemi* OR erythroblastic anemi* OR erythroblastic anaemi* OR iron overload* OR iron over‐load* OR hemoglobinopath* OR haemoglobinopath*)
#6 TS=(sickle OR sicklemi* OR sickled OR sickling OR meniscocyt* OR drepanocyt* OR "hemoglobin S" OR "hemoglobin SC" OR "hemoglobin SE" OR "hemoglobin SS" OR "hemoglobin C" OR "hemoglobin D" OR "haemoglobin S" OR "haemoglobin SC" OR "haemoglobin SE" OR "haemoglobin SS" OR "haemoglobin C" OR "haemoglobin D" OR "Hb S" OR "Hb SC" OR "Hb SE" OR "Hb SS" OR "Hb C" OR "Hb D" OR "SC disease")
#7 #5 OR #6
#8 #3 AND #4 AND #7

ClinicalTrials.gov
Other Terms: (thalassemia OR sickle cell anemia OR iron overload OR hemoglobinopathies) AND (iron chelation OR chelation therapy OR deferiprone OR deferoxamine OR deferasirox OR DFO OR iron reduction)

WHO ICTRP
Condition: thalassemia OR sickle cell anemia OR iron overload OR hemoglobinopathies
Intervention: iron chelation OR chelation therapy OR deferiprone OR deferoxamine OR deferasirox OR DFO OR iron reduction

ISRCTN
Condition: thalassemia OR sickle cell anemia OR iron overload OR hemoglobinopathies
Interventions: iron chelation OR chelation therapy OR deferiprone OR deferoxamine OR deferasirox OR DFO OR iron reduction

Appendix 2. The Risk Of Bias In Non‐randomised Studies of Interventions (ROBINS‐I) assessment tool

ROBINS‐I tool (Stage I)

Specify the review question

Participants

Experimental intervention

Control intervention

Outcomes

List the confounding areas relevant to all or most studies
List the possible co‐interventions that could be different between intervention groups and could have an impact on outcomes

The ROBINS‐I tool (Stage II): For each study

Specify a target trial specific to the study.

Design

Individually randomised or cluster randomised or matched

Participants

Experimental intervention

Control intervention

Is your aim for this study...?

□ to assess the effect of initiating intervention (as in an intention‐to‐treat analysis)

□ to assess the effect of initiating and adhering to intervention (as in a per protocol analysis)

Specify the outcome

Specify which outcome is being assessed for risk of bias (typically from among those earmarked for the Summary of Findings table). Specify whether this is a proposed benefit or harm of intervention.

Specify the numerical result being assessed

In case of multiple alternative analyses being presented, specify the numeric result (e.g. RR = 1.52 (95% CI 0.83 to 2.77) or a reference (e.g. to a table, figure or paragraph) that uniquely defines the result being assessed (or both).

Preliminary consideration of confounders

Complete a row for each important confounding area (i) listed in the review protocol; and (ii) relevant to the setting of this particular study, or which the study authors identified as potentially important.

'Important' confounding areas are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of the intervention. 'Validity' refers to whether the confounding variable or variables fully measure the area, while 'reliability' refers to the precision of the measurement (more measurement error means less reliability).

(i) Confounding areas listed in the review protocol

Confounding area

Measured variable(s)

Is there evidence that controlling for this variable was unnecessary?*

Is the confounding area measured validly and reliably by this variable (or these variables)?

OPTIONAL: is adjusting for this variable (alone) expected to favour the experimental or the control group?

Yes / No / No information

Favour intervention / Favour control / No information

(ii) Additional confounding areas relevant to the setting of this particular study, or which the study authors identified as important

Confounding area

Measured Variable(s)

Is there evidence that controlling for this variable was unnecessary?*

Is the confounding area measured validly and reliably by this variable (or these variables)?

OPTIONAL: is adjusting for this variable (alone) expected to favour the experimental or the control group?

Yes / No / No information

Favour intervention / Favour control / No information

* In the context of a particular study, variables can be demonstrated not to be confounders and so not included in the analysis: (a) if they are not predictive of the outcome; (b) if they are not predictive of intervention; or (c) because adjustment makes no or minimal difference to the estimated effect of the primary parameter. Note that “no statistically significant association” is not the same as “not predictive”.

Preliminary consideration of co‐interventions

Complete a row for each important co‐intervention (i) listed in the review protocol; and (ii) relevant to the setting of this particular study, or which the study authors identified as important.

'Important' co‐interventions are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of the intervention.

(i) Co‐interventions listed in the review protocol

Co‐intervention

Is there evidence that controlling for this co‐intervention was unnecessary (e.g. because it was not administered)?

Is presence of this co‐intervention likely to favour outcomes in the experimental or the control group

Favour experimental / Favour comparator / No information

Favour experimental / Favour comparator / No information

Favour experimental / Favour comparator / No information

(ii) Additional co‐interventions relevant to the setting of this particular study, or which the study authors identified as important

Co‐intervention

Is there evidence that controlling for this co‐intervention was unnecessary (e.g. because it was not administered)?

Is presence of this co‐intervention likely to favour outcomes in the experimental or the control group

Favour experimental / Favour comparator / No information

Favour experimental / Favour comparator / No information

Favour experimental / Favour comparator / No information

Risk of bias assessment (cohort‐type studies)

Bias domain

Signalling questions

Elaboration

Response options

Bias due to confounding

1.1 Is there potential for confounding of the effect of intervention in this study?

IfN or PN to1.1: the study can be considered to be at low risk of bias due to confounding and no further signalling questions need be considered

In rare situations, such as when studying harms that are very unlikely to be related to factors that influence treatment decisions, no confounding is expected and the study can be considered to be at low risk of bias due to confounding, equivalent to a fully randomised trial.

There is no NI (No information) option for this signalling question.

Y / PY / PN / N

If Y or PY to 1.1: determine whether there is a need to assess time‐varying confounding:

1.2. Was the analysis based on splitting participants’ follow up time according to intervention received?

If N orPN, answer questions relating to baseline confounding (1.4 to 1.6)

If Y orPY, proceed to question 1.3.

If participants could switch between intervention groups then associations between intervention and outcome may be biased by time‐varying confounding. This occurs when prognostic factors influence switches between intended interventions.

NA / Y / PY / PN / N / NI

1.3. Were intervention discontinuations or switches likely to be related to factors that are prognostic for the outcome?

If N or PN, answer questions relating to baseline confounding (1.4 to 1.6)

If Y orPY, answer questions relating to both baseline and time‐varying confounding (1.7 and 1.8)

If intervention switches are unrelated to the outcome, for example when the outcome is an unexpected harm, then time‐varying confounding will not be present and only control for baseline confounding is required.

NA / Y / PY / PN / N / NI

Questions relating to baseline confounding only

1.4. Did the authors use an appropriate analysis method that controlled for all the important confounding areas?

Appropriate methods to control for measured confounders include stratification, regression, matching, standardization, and inverse probability weighting. They may control for individual variables or for the estimated propensity score. Inverse probability weighting is based on a function of the propensity score. Each method depends on the assumption that there is no unmeasured or residual confounding.

NA / Y / PY / PN / N / NI

1.5.If Y or PY to1.4: were confounding areas that were controlled for measured validly and reliably by the variables available in this study?

Appropriate control of confounding requires that the variables adjusted for are valid and reliable measures of the confounding domains. For some topics, a list of valid and reliable measures of confounding domains will be specified in the review protocol but for others such a list may not be available. Study authors may cite references to support the use of a particular measure. If authors control for confounding variables with no indication of their validity or reliability pay attention to the subjectivity of the measure. Subjective measures (e.g. based on self‐report) may have lower validity and reliability than objective measures such as lab findings.

NA / Y / PY / PN / N / NI

1.6. Did the authors control for any post‐intervention variables?

Controlling for post‐intervention variables is not appropriate. Controlling for mediating variables estimates the direct effect of intervention and may introduce confounding. Controlling for common effects of intervention and outcome causes bias.

NA / Y / PY / PN / N / NI

Questions relating to baseline and time‐varying confounding

1.7. Did the authors use an appropriate analysis method that adjusted for all the important confounding areas and for time‐varying confounding?

Adjustment for time‐varying confounding is necessary to estimate per‐protocol effects in both randomised trials and NRSI. Appropriate methods include those based on inverse‐probability weighting. Standard regression models that include time‐updated confounders may be problematic if time‐varying confounding is present.

NA / Y / PY / PN / N / NI

1.8. IfY orPY to1.7: Were confounding areas that were adjusted for measured validly and reliably by the variables available in this study?

See 1.5 above.

NA / Y / PY / PN / N / NI

Risk of bias judgement

Low ‐ no confounding expected.

Low / Moderate / Serious / Critical / NI

Moderate ‐ confounding expected, all known important confounding domains appropriately measured and controlled for;

and

Reliability and validity of measurement of important domains were sufficient, such that we do not expect serious residual confounding.

Serious ‐ at least one known important domain was not appropriately measured, or not controlled for;

or

Reliability or validity of measurement of a important domain was low enough that we expect serious residual confounding.

Critical ‐ confounding inherently not controllable, or the use of negative controls strongly suggests unmeasured confounding.

Optional: what is the predicted direction of bias due to confounding?

Can the true effect estimate be predicted to be greater or less than the estimated effect in the study because one or more of the important confounding domains was not controlled for? Answering this question will be based on expert knowledge and results in other studies and therefore can only be completed after all of the studies in the body of evidence have been reviewed. Consider the potential effect of each of the unmeasured domains and whether all important confounding domains not controlled for in the analysis would be likely to change the estimate in the same direction, or if one important confounding domain that was not controlled for in the analysis is likely to have a dominant impact.

Favours experimental / Favours comparator / Unpredictable

Bias in selection of participants into the study

2.1. Was selection of participants into the study (or into the analysis) based on participant characteristics observed after the start of intervention?

This domain is concerned only with selection into the study based on participant characteristics observed after the start of intervention. Selection based on characteristics observed before the start of intervention can be addressed by controlling for imbalances between intervention and control groups in baseline characteristics that are prognostic for the outcome (baseline confounding).

Y / PY / PN / N / NI

IfN orPN to2.1: go to 2.4

2.2. IfY orPY to2.1: were the post‐intervention variables that influenced selection likely to be associated with intervention

Selection bias occurs when selection is related to an effect of either intervention or a cause of intervention and an effect of either the outcome or a cause of the outcome. Therefore, the result is at risk of selection bias if selection into the study is related to both the intervention and the outcome.

NA / Y / PY / PN / N / NI

2.3 If Y orPY to2.2: were the post‐intervention variables that influenced selection likely to be influenced by the outcome or a cause of the outcome?

NA / Y / PY / PN / N / NI

2.4. Do start of follow up and start of intervention coincide for most participants?

If participants are not followed from the start of the intervention then a period of follow up has been excluded, and individuals who experienced the outcome soon after intervention will be missing from analyses. This problem may occur when prevalent, rather than new (incident), users of the intervention are included in analyses.

Y / PY / PN / N / NI

2.5. IfY orPY to2.2 and2.3, or N orPN to 2.4: were adjustment techniques used that are likely to correct for the presence of selection biases?

It is in principle possible to correct for selection biases, for example by using inverse probability weights to create a pseudo‐population in which the selection bias has been removed, or by modelling the distributions of the missing participants or follow up times and outcome events and including them using missing data methodology. However such methods are rarely used and the answer to this question will usually be “No”

NA / Y / PY / PN / N / NI

Risk of bias judgement

Low ‐ all participants who would have been eligible for the target trial were included in the study and start of follow up and start of intervention coincide for all subjects.

Low / Moderate / Serious / Critical / NI

Moderate ‐ selection into the study may have been related to intervention and outcome, but the authors used appropriate methods to adjust for the selection bias; or Start of follow up and start of intervention do not coincide for all participants, but (a) the proportion of participants for which this was the case was too low to induce important bias; (b) the authors used appropriate methods to adjust for the selection bias; or (c) the review authors are confident that the rate (hazard) ratio for the effect of intervention remains constant over time.

Serious ‐ selection into the study was related to intervention and outcome;

or

Start of follow up and start of intervention do not coincide, and a potentially important amount of follow‐up time is missing from analyses, and the rate ratio is not constant over time.

Critical ‐ selection into the study was strongly related to intervention and outcome;

or

A substantial amount of follow‐up time is likely to be missing from analyses, and the rate ratio is not constant over time.

Optional: what is the predicted direction of bias due to selection of participants into the study?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterized either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias in classification of interventions

3.1 Were intervention groups clearly defined?

A pre‐requisite for an appropriate comparison of interventions is that the interventions are well defined. Ambiguity in the definition may lead to bias in the classification of participants. For individual‐level interventions, criteria for considering individuals to have received each intervention should be clear and explicit, covering issues such as type, setting, dose, frequency, intensity and/or timing of intervention. For population‐level interventions (e.g. measures to control air pollution), the question relates to whether the population is clearly defined, and the answer is likely to be ‘Yes’.

Y / PY / PN / N / NI

3.2 Was the information used to define intervention groups recorded at the start of the intervention?

In general, if information about interventions received is available from sources that could not have been affected by subsequent outcomes, then differential misclassification of intervention status is unlikely. Collection of the information at the time of the intervention makes it easier to avoid such misclassification. For population‐level interventions (e.g. measures to control air pollution), the answer to this question is likely to be ‘Yes’.

Y / PY / PN / N / NI

3.3 Could classification of intervention status have been affected by knowledge of the outcome or risk of the outcome?

Collection of the information at the time of the intervention may not be sufficient to avoid bias. The way in which the data are collected for the purposes of the NRSI should also avoid misclassification.

Y / PY / PN / N / NI

Risk of bias judgement

Low ‐ intervention status is well defined and based solely on information collected at the time of intervention.

Low / Moderate / Serious / Critical / NI

Moderate ‐ intervention status is well defined but some aspects of the assignments of intervention status were determined retrospectively

Serious ‐ intervention status is not well defined, or major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome.

Critical ‐ (unusual) An extremely high amount of misclassification of intervention status, e.g. because of unusually strong recall biases.

Optional: what is the predicted direction of bias due to measurement of outcomes or interventions?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterized either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias due to departures from intended interventions

4.1. Was the intervention implemented successfully for most participants?

Consider the success of implementation of the intervention in the context of its complexity. Was recommended practice followed by those administering the intervention?

Y / PY / PN / N / NI

If your aim for this study is to assess the effect of initiating and adhering to intervention (as in a per‐protocol analysis), answer questions 4.2 to 4.4

4.2. Did study participants adhere to the assigned intervention regimen?

Lack of adherence to assigned intervention includes cessation of intervention, crossovers to the comparator intervention and switches to another active intervention. We distinguish between analyses where:

(1) intervention switches led to follow up time being assigned to the new intervention; and

(2) intervention switches (including cessation of intervention) where follow up time remained allocated to the original intervention;

(3) is addressed under time‐varying confounding, and should not be considered further here.

Consider available information on the proportion of study participants who continued with their assigned intervention throughout follow up. Was lack of adherence sufficient to impact the intervention effect estimate?

NA/ Y / PY / PN / N / NI

4.3. Were important co‐interventions balanced across intervention groups?

Consider the co‐interventions that are likely to affect the outcome and to have been administered in the context of this study, based on the preliminary consideration of co‐interventions and available literature. Consider whether these co‐interventions are balanced between intervention groups.

NA/ Y / PY / PN / N / NI

4.4. IfN orPN to4.1, 4.2 or4.3: were adjustment techniques used that are likely to correct for these issues?

Such adjustment techniques include inverse‐probability weighting to adjust for censoring at deviation from intended intervention, or inverse probability weighting of marginal structural models to adjust for time‐varying confounding. Specialist advice may be needed to assess studies that used these approaches.

NA / Y / PY / PN / N / NI

Risk of bias judgement

Low ‐ no bias due to deviation from the intended intervention is expected, for example if both the intervention and comparator are implemented over a short time period, and subsequent interventions are part of routine medical care, or if the specified comparison relates to initiation of intervention regardless of whether it is continued.

Low / Moderate / Serious / Critical / NI

Moderate ‐ bias due to deviation from the intended intervention is expected, and switches, co‐interventions, and some problems with intervention fidelity are appropriately measured and adjusted for in the analyses. Alternatively, most (but not all) deviations from intended intervention reflect the natural course of events after initiation of intervention.

Serious ‐ switches in treatment, co‐interventions, or problems with implementation fidelity are apparent and are not adjusted for in the analyses.

Critical ‐ substantial deviations from the intended intervention are present and are not adjusted for in the analysis.

Optional: what is the predicted direction of bias due to departures from the intended interventions?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterized either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias due to missing data

5.1 Were there missing outcome data?

This aims to elicit whether the proportion of missing observations is likely to result in missing information that could substantially impact our ability to answer the question being addressed. Guidance will be needed on what is meant by ‘reasonably complete’. One aspect of this is that review authors would ideally try and locate an analysis plan for the study.

Y / PY / PN / N / NI

5.2 Were participants excluded due to missing data on intervention status?

Missing intervention status may be a problem. This requires that the intended study sample is clear, which it may not be in practice.

Y / PY / PN / N / NI

5.3 Were participants excluded due to missing data on other variables needed for the analysis?

This question relates particularly to participants excluded from the analysis because of missing information on confounders that were controlled for in the analysis.

Y / PY / PN / N / NI

5.4 If Y orPY to 5.1, 5.2 or5.3: are the proportion of participants and reasons for missing data similar across interventions?

This aims to elicit whether either (i) differential proportion of missing observations or (ii) differences in reasons for missing observations could substantially impact on our ability to answer the question being addressed.

NA / Y / PY / PN / N / NI

5.5If Y or PY to5.1, 5.2 or5.3: were appropriate statistical methods used to account for missing data?

It is important to assess whether assumptions employed in analyses are clear and plausible. Both content knowledge and statistical expertise will often be required for this. For instance, use of a statistical method such as multiple imputation does not guarantee an appropriate answer. Review authors should seek naïve (complete‐case) analyses for comparison, and clear differences between complete‐case and multiple imputation‐based findings should lead to careful assessment of the validity of the methods used.

NA / Y / PY / PN / N / NI

Risk of bias judgement

Low ‐ data were reasonably complete; or Proportions of and reasons for missing participants were similar across intervention groups; or Analyses that addressed missing data are likely to have removed any risk of bias.

Low / Moderate / Serious / Critical / NI

Moderate ‐ proportions of missing participants differ across interventions; or Reasons for missingness differ minimally across interventions; and Missing data were not addressed in the analysis.

Serious ‐ proportions of missing participants differ substantially across interventions; or Reasons for missingness differ substantially across interventions; and Missing data were addressed inappropriately in the analysis; or The nature of the missing data means that the risk of bias cannot be removed through appropriate analysis.

Critical ‐ (unusual) There were critical differences between interventions in participants with missing data that were not, or could not, be addressed through appropriate analysis.

Optional: what is the predicted direction of bias due to missing data?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterized either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias in measurement of outcomes

6.1 Could the outcome measure have been influenced by knowledge of the intervention received?

Some outcome measures involve negligible assessor judgment, e.g. all‐cause mortality or non‐repeatable automated laboratory assessments. Risk of bias due to measurement of these outcomes would be expected to be low.

Y / PY / PN / N / NI

6.2 Were outcome assessors aware of the intervention received by study participants?

If outcome assessors were blinded to intervention status, the answer to this question would be ‘No’. In other situations, outcome assessors may be unaware of the interventions being received by participants despite there being no active blinding by the study investigators; the answer this question would then also be ‘No’. In studies where participants report their outcomes themselves, for example in a questionnaire, the outcome assessor is the study participant. In an observational study, the answer to this question will usually be ‘Yes’ when the participants report their outcomes themselves.

Y / PY / PN / N / NI

6.3 Were the methods of outcome assessment comparable across intervention groups?

Comparable assessment methods (i.e. data collection) would involve the same outcome detection methods and thresholds, same time point, same definition, and same measurements

Y / PY / PN / N / NI

6.4 Were any systematic errors in measurement of the outcome related to intervention received?

This question refers to differential misclassification of outcomes. Systematic errors in measuring the outcome, if present, could cause bias if they are related to intervention or to a confounder of the intervention‐outcome relationship. This will usually be due either to outcome assessors being aware of the intervention received or to non‐comparability of outcome assessment methods, but there are examples of differential misclassification arising despite these controls being in place.

Y / PY / PN / N / NI

Risk of bias judgement

Low ‐ the methods of outcome assessment were comparable across intervention groups;

and

The outcome measure was unlikely to be influenced by knowledge of the intervention received by study participants (i.e. is objective) or the outcome assessors were unaware of the intervention received by study participants;

and

Any error in measuring the outcome is unrelated to intervention status.

Low / Moderate / Serious / Critical / NI

Moderate ‐ the methods of outcome assessment were comparable across intervention groups;

and

The outcome measure is only minimally influenced by knowledge of the intervention received by study participants;

and

Any error in measuring the outcome is only minimally related to intervention status.

Serious ‐ the methods of outcome assessment were not comparable across intervention groups;

or

The outcome measure was subjective (i.e. likely to be influenced by knowledge of the intervention received by study participants) and was assessed by outcome assessors aware of the intervention received by study participants;

or

Error in measuring the outcome was related to intervention status.

Critical ‐ the methods of outcome assessment were so different that they cannot reasonably be compared across intervention groups.

Optional: what is the predicted direction of bias due to measurement of outcomes?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterized either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Bias in selection of the reported result

Is the reported effect estimate unlikely to be selected, on the basis of the results, from...

7.1. ... multiple outcome measurements within the outcome domain?

For a specified outcome domain, it is possible to generate multiple effect estimates for different measurements. If multiple measurements were made, but only one or a subset is reported, there is a risk of selective reporting on the basis of results.

Y / PY / PN / N / NI

7.2 ... multiple analyses of the intervention‐outcome relationship?

Because of the limitations of using data from non‐randomized studies for analyses of effectiveness (need to control confounding, substantial missing data, etc), analysts may implement different analytic methods to address these limitations. Examples include unadjusted and adjusted models; use of final value vs change from baseline vs analysis of covariance; different transformations of variables; a continuously scaled outcome converted to categorical data with different cutpoints; different sets of covariates used for adjustment; and different analytic strategies for dealing with missing data. Application of such methods generates multiple effect estimates for a specific outcome metric. If the analyst does not prespecify the methods to be applied, and multiple estimates are generated but only one or a subset is reported, there is a risk of selective reporting on the basis of results.

Y / PY / PN / N / NI

7.3 ... different subgroups?

Particularly with large cohorts often available from routine data sources, it is possible to generate multiple effect estimates for different subgroups or simply to omit varying proportions of the original cohort. If multiple estimates are generated but only one or a subset is reported, there is a risk of selective reporting on the basis of results.

Y / PY / PN / N / NI

Risk of bias judgement

Low ‐ there is clear evidence (usually through examination of a pre‐registered protocol or statistical analysis plan) that all reported results correspond to all intended outcomes, analyses and sub‐cohorts.

Low / Moderate / Serious / Critical / NI

Moderate ‐ the outcome measurements and analyses are consistent with an a priori plan;

or

are clearly defined and both internally and externally consistent;

and

there is no indication of selection of the reported analysis from among multiple analyses;

and

there is no indication of selection of the cohort or subgroups for analysis and reporting on the basis of the results.

Serious ‐ outcome measurements or analyses are internally or externally inconsistent; or There is a high risk of selective reporting from among multiple analyses; or The cohort or subgroup is selected from a larger study for analysis and appears to be reported on the basis of the results.

Critical ‐ there is evidence or strong suspicion of selective reporting of results, and the unreported results are likely to be substantially different from the reported results.

Optional: What is the predicted direction of bias due to selection of the reported result?

If the likely direction of bias can be predicted, it is helpful to state this. The direction might be characterized either as being towards (or away from) the null, or as being in favour of one of the interventions.

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Overall bias

Risk of bias judgement

Low ‐ the study is judged to be at low risk of bias for all domains.

Low / Moderate / Serious / Critical / NI

Moderate ‐ the study is judged to be at low or moderate risk of bias for all domains.

Serious ‐ the study is judged to be at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.

Critical ‐ the study is judged to be at critical risk of bias in at least one domain.

No information ‐ there is no clear indication that the study is at serious or critical risk of bias and there is a lack of information in one or more key domains of bias (a judgement is required for this).

Optional:

what is the overall predicted direction of bias for this outcome?

Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

Study flow diagram.
Figures and Tables -
Figure 1

Study flow diagram.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figures and Tables -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figures and Tables -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Comparison 1 DFP versus DFO, Outcome 1 Adherence to iron chelation therapy (%, SD).
Figures and Tables -
Analysis 1.1

Comparison 1 DFP versus DFO, Outcome 1 Adherence to iron chelation therapy (%, SD).

Comparison 1 DFP versus DFO, Outcome 2 SAEs (from therapy, disease, non‐adherence).
Figures and Tables -
Analysis 1.2

Comparison 1 DFP versus DFO, Outcome 2 SAEs (from therapy, disease, non‐adherence).

Comparison 1 DFP versus DFO, Outcome 3 All‐cause mortality.
Figures and Tables -
Analysis 1.3

Comparison 1 DFP versus DFO, Outcome 3 All‐cause mortality.

Comparison 1 DFP versus DFO, Outcome 4 Iron overload: defined as proportion of participants with serum ferritin ≥ 800 (µg/L).
Figures and Tables -
Analysis 1.4

Comparison 1 DFP versus DFO, Outcome 4 Iron overload: defined as proportion of participants with serum ferritin ≥ 800 (µg/L).

Comparison 1 DFP versus DFO, Outcome 5 Organ damage.
Figures and Tables -
Analysis 1.5

Comparison 1 DFP versus DFO, Outcome 5 Organ damage.

Comparison 1 DFP versus DFO, Outcome 6 Other AEs related to iron chelation.
Figures and Tables -
Analysis 1.6

Comparison 1 DFP versus DFO, Outcome 6 Other AEs related to iron chelation.

Comparison 2 DFX versus DFO, Outcome 1 Adherence to iron chelation therapy (%, SD).
Figures and Tables -
Analysis 2.1

Comparison 2 DFX versus DFO, Outcome 1 Adherence to iron chelation therapy (%, SD).

Comparison 2 DFX versus DFO, Outcome 2 SAEs.
Figures and Tables -
Analysis 2.2

Comparison 2 DFX versus DFO, Outcome 2 SAEs.

Comparison 2 DFX versus DFO, Outcome 3 All‐cause mortality (thalassaemia).
Figures and Tables -
Analysis 2.3

Comparison 2 DFX versus DFO, Outcome 3 All‐cause mortality (thalassaemia).

Comparison 2 DFX versus DFO, Outcome 4 Proportion of participants with iron overload (thalassaemia).
Figures and Tables -
Analysis 2.4

Comparison 2 DFX versus DFO, Outcome 4 Proportion of participants with iron overload (thalassaemia).

Comparison 2 DFX versus DFO, Outcome 5 Other AEs related to iron chelation ‐ (thalassaemia).
Figures and Tables -
Analysis 2.5

Comparison 2 DFX versus DFO, Outcome 5 Other AEs related to iron chelation ‐ (thalassaemia).

Comparison 2 DFX versus DFO, Outcome 6 Total AEs (thalassaemia).
Figures and Tables -
Analysis 2.6

Comparison 2 DFX versus DFO, Outcome 6 Total AEs (thalassaemia).

Comparison 2 DFX versus DFO, Outcome 7 Other AEs related to iron chelation (SCD).
Figures and Tables -
Analysis 2.7

Comparison 2 DFX versus DFO, Outcome 7 Other AEs related to iron chelation (SCD).

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 1 Adherence to iron chelation therapy.
Figures and Tables -
Analysis 3.1

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 1 Adherence to iron chelation therapy.

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 2 Incidence of SAEs.
Figures and Tables -
Analysis 3.2

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 2 Incidence of SAEs.

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 3 All‐cause mortality.
Figures and Tables -
Analysis 3.3

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 3 All‐cause mortality.

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 4 Incidence of organ damage (renal event).
Figures and Tables -
Analysis 3.4

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 4 Incidence of organ damage (renal event).

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 5 Other AEs related to iron chelation.
Figures and Tables -
Analysis 3.5

Comparison 3 DFX film‐coated tablet versus DFX dispersible tablet, Outcome 5 Other AEs related to iron chelation.

Comparison 4 DFP and DFO versus DFP, Outcome 1 Incidence of SAEs.
Figures and Tables -
Analysis 4.1

Comparison 4 DFP and DFO versus DFP, Outcome 1 Incidence of SAEs.

Comparison 4 DFP and DFO versus DFP, Outcome 2 All‐cause mortality.
Figures and Tables -
Analysis 4.2

Comparison 4 DFP and DFO versus DFP, Outcome 2 All‐cause mortality.

Comparison 4 DFP and DFO versus DFP, Outcome 3 Incidence of chelation therapy‐related AEs.
Figures and Tables -
Analysis 4.3

Comparison 4 DFP and DFO versus DFP, Outcome 3 Incidence of chelation therapy‐related AEs.

Comparison 5 DFP and DFO versus DFO, Outcome 1 Other AEs related to iron chelation.
Figures and Tables -
Analysis 5.1

Comparison 5 DFP and DFO versus DFO, Outcome 1 Other AEs related to iron chelation.

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 1 Adherence to iron chelation therapy rates.
Figures and Tables -
Analysis 6.1

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 1 Adherence to iron chelation therapy rates.

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 2 Incidence of SAE.
Figures and Tables -
Analysis 6.2

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 2 Incidence of SAE.

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 3 All‐cause mortality.
Figures and Tables -
Analysis 6.3

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 3 All‐cause mortality.

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 4 Organ damage (serum creatinine (≥33%) above baseline in 2 consecutive occasions).
Figures and Tables -
Analysis 6.4

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 4 Organ damage (serum creatinine (≥33%) above baseline in 2 consecutive occasions).

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 5 Other AEs related to iron chelation.
Figures and Tables -
Analysis 6.5

Comparison 6 DFP/DFX versus DFP/DFO, Outcome 5 Other AEs related to iron chelation.

Summary of findings for the main comparison. DFP compared to DFO for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

DFP compared to DFO for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Patient or population: improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Setting: outpatients
Intervention: DFP
Comparison: DFO

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with DFO

Risk with DFP

Adherence to iron chelation therapy (per cent, SD)

242

(4 RCTs)

⊕⊝⊝⊝
VERY LOW 1 2

We found considerable heterogeneity and identified age as possible cause: 1 trial in children 10 years or older and 1 conducted in participants 18 or older

SAEs (from therapy, disease, non‐adherence) Agranulocytosis**

Study population

RR 7.88
(99% CI 0.18 to 352.39)

88
(1 RCT)

⊕⊝⊝⊝
VERY LOW 3 4

No SAEs were reported in the second trial reporting this outcome

15 per 1000

118 per 1,000

(7 to 1000)

All‐cause mortality

Study population

RR 0.44
(95% CI 0.12 to 1.63)

88
(1 RCT)

⊕⊝⊝⊝
VERY LOW 3 4

No deaths occurred in the second trial reporting this outcome

146 per 1000

64 per 1000
(18 to 239)

Sustained adherence ‐ not measured

Sustained adherence is reported as adherence as all trials were longer than 6 months and only end of trial adherence numbers were provided

Quality of life ‐ not reported

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; DFO: deferoxamine; DFP: deferiprone; RCT: randomised controlled trial; RR: risk ratio; SD: standard deviation.

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

1 We downgraded the quality of evidence by 1 for risk of bias due to high or uncertain risk of bias due to lack of blinding of participants and personnel in all four RCTs, as well as selection bias (Olivieri 1997), attrition bias (El Beshlawy 2008; Olivieri 1997), reporting bias (El Beshlawy 2008; Pennell 2006), and other bias (Pennell 2006).
2 We downgraded the quality of evidence by 2 for inconsistency due to considerable heterogeneity in comparison.
3 We downgraded the quality of evidence by 2 for imprecision due to very wide CIs that included clinically important benefits and harms.
4 We downgraded the quality of evidence by 1 for indirectness as the trial was conducted in participants with thalassaemia intermedia only; a milder form of thalassaemia

** Risk estimate based on: Tricta F, Uetrecht J, Galanello R, et al. Deferiprone‐induced agranulocytosis: 20 years of clinical observations. American Journal of Hematology. 2016;91(10):1026‐1031. doi:10.1002/ajh.24479.

Figures and Tables -
Summary of findings for the main comparison. DFP compared to DFO for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Summary of findings 2. DFX compared to DFO for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

DFX compared to DFO for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Patient or population: improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Setting: outpatients
Intervention: DFX
Comparison: DFO

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with DFO

Risk with DFX

Adherence to iron chelation therapy (per cent, SD)

The mean adherence to iron chelation therapy (per cent, SD) was 0

MD 1.4 lower
(3.66 lower to 0.86 higher)

197
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1 2

Narrative report of adherence for 2 trials as either no or incompatible data to enable comparisons

SAEs ‐ thalassaemia‐related SAEs

Study population

247
(2 RCTs)

⊕⊝⊝⊝
VERY LOW 1 2

There were no SAEs to report in one trial so no estimate of effect

see comment

see comment

SAEs ‐ SCD‐related SAEs

Study population

RR 1.08
(95% CI 0.77 to 1.51)

195
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1 2

429 per 1000

463 per 1000
(330 to 647)

Incidence of SCD‐related SAEs ‐pain crisis

Study population

RR 1.05
(95% CI 0.68 to 1.62)

195
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1 2

317 per 1000

333 per 1000
(216 to 514)

All‐cause mortality (thalassaemia)

Study population

RR 0.96
(95%CI 0.06 to 15.06)

240
(2 RCTs)

⊕⊝⊝⊝
VERY LOW 1 2

8 per 1000

8 per 1000
(1 to 128)

Sustained adherence ‐ not measured

Sustained adherence is reported as adherence as all trials were longer than 6 months and only end of trial adherence reported

Quality of life ‐ not reported

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; DFO: deferoxamine; DFX: deferasirox; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio; SD: standard deviation.

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

1 We downgraded the quality of evidence by 2 due to high or uncertain risk of bias in several domains
2 We downgraded the quality of evidence by 1 due to imprecision as CIs are wide and only 1 trial with data in comparison

Figures and Tables -
Summary of findings 2. DFX compared to DFO for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Summary of findings 3. DFX film‐coated tablet compared to DFX dispersible tablet for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

DFX film‐coated tablet compared to DFX dispersible tablet for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Patient or population: improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Setting: outpatients
Intervention: DFX film‐coated tablet
Comparison: DFX dispersible tablet

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with DFX dispersible tablet

Risk with DFX film‐coated tablet

Adherence to iron chelation therapy (n, N)

Study population

RR 1.10
(95% CI 0.99 to 1.22)

173
(1 RCT)

⊕⊕⊝⊝
LOW 1

849 per 1000

934 per 1000
(840 to 1000)

Incidence of SAEs

Study population

RR 1.22
(95% CI 0.62 to 2.37)

173
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1 2

151 per 1,000

184 per 1000
(94 to 358)

All‐cause mortality

Study population

RR 2.97
(95% CI 0.12 to 71.81)

173
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1 2

0 per 1000

0 per 1000
(0 to 0)

Sustained adherence ‐ not measured

Reported as adherence as trial was 6 months in duration and end of trial adherence reported

Quality of life ‐ not reported

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; DFX: deferasirox; RCT: randomised controlled trial; RR: risk ratio; SAEs: serious adverse events

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

1 We downgraded the quality of evidence by 2 for risk of bias due to high or unclear risk of bias in all domains
2 We downgraded the quality of evidence by 1 for imprecision due to wide CIs

Figures and Tables -
Summary of findings 3. DFX film‐coated tablet compared to DFX dispersible tablet for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Summary of findings 4. DFP and DFO compared to DFP for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

DFP and DFO compared to DFP for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Patient or population: improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Setting: outpatients
Intervention: DFP and DFO
Comparison: DFP

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with DFP

Risk with DFP and DFO

Adherence to iron chelation therapy (per cent, SD)

see comment

see comment

289

(3 RCTs)

⊕⊝⊝⊝
VERY LOW 1 2

Reported as narrative as no comparisons possible

Incidence of SAEs

Study population

RR 0.15
(95% CI 0.01 to 2.81)

213
(1 RCT)

⊕⊕⊝⊝
LOW 2 3

28 per 1,000

4 per 1,000
(0 to 78)

All‐cause mortality

Study population

RR 0.77
(95% CI 0.18 to 3.35)

237
(2 RCTs)

⊕⊝⊝⊝
VERY LOW 3 4

33 per 1,000

26 per 1,000
(6 to 112)

Sustained adherence ‐ not measured

Sustained adherence is reported as adherence as trial duration longer than 6 months and reports adherence for length of trial

Quality of life ‐ not reported

Quality of life was either not reported or no validated instruments were used

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; DFO: deferoxamine DFP: deferiprone; RCT: randomised controlled trial; RR: risk ratio; SAEs: serious adverse events; SD: standard deviation.

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 We downgraded the quality of evidence by 2 for risk of bias as there was high or uncertain risk of bias in most domains in 3 out of 4 trials
2 We downgraded the quality of evidence by 1 due to high or unclear risk of bias in 3 domains
3 We downgraded the quality of evidence by 1 for imprecision due to wide CIs
4 We downgraded the quality of evidence by 2 for risk of bias as there was high or uncertain risk of bias in 1 of the trials in the comparison

Figures and Tables -
Summary of findings 4. DFP and DFO compared to DFP for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Summary of findings 5. DFP and DFO compared to DFO for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

DFP and DFO compared to DFO for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Patient or population: improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Setting: outpatients
Intervention: DFP and DFO
Comparison: DFO

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with DFO

Risk with DFP and DFO

Adherence to iron chelation therapy (per cent, SD)

see comment

see comment

205

(4 RCTs)

⊕⊕⊝⊝
LOW 1

Reported as narrative only as adherence in combined group not reported for combination therapy

Incidence of SAEs

Study population

205

(4 RCTs)

⊕⊕⊝⊝
LOW 1

3 trials report no SAEs; SAES are not reported in one trial

see comment

see comment

All‐cause mortality

Study population

205

(4 RCTs)

⊕⊕⊝⊝
LOW 1

no deaths reported

see comment

see comment

Sustained adherence ‐ not measured

Sustained adherence reported as adherence as trial duration was longer than 6 months and adherence reported at end of trial

Quality of life ‐ not reported

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

DFO: deferoxamine; DFP: deferiprone; SAEs: serious adverse events.

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 We downgraded the quality of evidence by 2 for risk of bias as high or unclear risk of bias in all domains

Figures and Tables -
Summary of findings 5. DFP and DFO compared to DFO for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Summary of findings 6. DFP and DFO compared to DFP and DFX for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

DFP/DFO compared to DFP/DFX for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Patient or population: improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Setting: outpatients
Intervention: DFP/DFO
Comparison: DFP/DFX

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with DFP/DFX

Risk with DFP/DFO

Adherence to iron chelation therapy rates (n,N) ‐ 1 year

Study population

RR 0.84
(95% CI 0.72 to 0.99)

96
(1 RCT)

⊕⊕⊝⊝
LOW 1 2

938 per 1000

788 per 1000
(675 to 928)

Incidence of SAE

Study population

RR 1.00
(95% CI 0.06 to 15.53)

96
(1 RCT)

⊕⊝⊝⊝
VERY LOW1 2 3

21 per 1,000

21 per 1000
(1 to 324)

All‐cause mortality ‐ at 1 year ‐ trial end

Study population

Not estimable

96
(1 RCT)

⊕⊕⊝⊝
LOW 1 2

No deaths were reported

0 per 1000

0 per 1000
(0 to 0)

Sustained adherence ‐ not measured

Sustained adherence is reported as adherence as trial was 1 year in duration and end of trial adherence reported

Quality of life see comment

The study uses SF36 to measure quality of life, the results are presented as a graph. Quality of life increased in both trial arms with no significant difference between trial arms P = 0.860

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; DFO: deferoxamine; DFP: deferiprone; DFX: deferasirox; RCT: randomised controlled trial; RR: risk ratio.

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 We downgraded the quality of evidence by 1 for risk of bias as there was high or unclear risk of bias in 3 domains
2 We downgraded the quality of evidence by 1 for indirectness as the trial included children 10 ‐ 18 with severe iron overload
3 We downgraded the quality of evidence by 1 for imprecision as the comparison has wide CIs

Figures and Tables -
Summary of findings 6. DFP and DFO compared to DFP and DFX for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Summary of findings 7. Medication management compared to standard care for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Medication management compared to standard care for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia

Patient or population: improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Setting: outpatient
Intervention: medication management
Comparison: standard care

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with standard care

Risk with medication management

Adherence to iron chelation therapy ‐ not reported

Adherence was only reported in the intervention group and therefore no comparative data

SAEs ‐ not reported

Mortality ‐ not reported

Sustained adherence

Adherence was only reported in the intervention group and therefore no comparative data

Quality of life
assessed with: PedsQLTM HRQoL total score

48
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1 2

Medication management: 63.51 (51.75 – 84.54); standard care: 49.84 (41.9 – 60.81)

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

RCT: randomised controlled trial; SAEs: serious adverse events.

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 We downgraded the quality of evidence for indirectness by 2 because most outcomes were only reported in the medication management group
2 We downgraded the quality of evidence by 2 for risk of bias due to high or uncertain risk of bias in all domains

Figures and Tables -
Summary of findings 7. Medication management compared to standard care for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
Table 1. Adherence Measurement and Results Table

STUDY

HOW ADHERENCE MEASURED

RESULTS

Aydinok 2007

  • Drug accounting at each visit (by counting the returned empty blisters of DFP and used vials of DFO)

  • Trial‐specific designed questionnaire completed by the participants or their legal representative/guardian (or both) at quarterly intervals

  • Compliance was generally excellent during the entire trial period

  • 1 participant in the DFP treatment arm who missed more than 1 chelation dose per week because of problems with swallowing

Badawy 2010

  • Questionnaire on chelation therapy, reasons for non‐compliance, side effects, life activities, transfusion regimen

  • Group II and group I were more compliant to chelation therapy but difference was statistically non significant

  • Non‐compliant participants (compliance less than 50%) showed increase in their SF levels in all studied groups

  • In non‐compliant participants the reduction in SF levels was higher in group I and III than in group II but difference was statistically non significant

Bahnasawy 2017

  • Clinical pharmacist analysed data to detect unnecessary drug therapy, need for additional drug therapy, ineffective drug product, dosage too low, adverse drug reaction, dosage too high, non‐compliance

  • All 24 participants in intervention group had non‐adherence at baseline and 3 where non‐adherent at end of trial

  • No data on control group

Calvaruso 2015

  • Counting the number of DFP pills in each returned bag

  • Assessing the number of infusions of DFO registered on the electronic pump

  • DFP compliance rate: 85%

  • DFO compliance rate: 76%

El Beshlawy 2008

  • Counting the returned empty blisters of DFP

  • Counting used vials of DFO

  • 4 participants with DFO‐based regimen excluded from the trial due to lack of compliance

  • Compliance was otherwise excellent during the entire trial period

  • Majority of participants had no problems with the intake and swallowing of the DFP tablets

  • 80% of participants in the combination arm and 76% of participants in the DFO monotherapy arm complained about difficulties in the parenteral use of DFO or problems to insert a needle

Elalfy 2015

  • Counting of returned tablets for the oral chelators

  • Counting vials for DFO

  • The percentage of actual dose that patient had taken in relation to the total prescribed dose was calculated

  • DFP/DFX: 95%

  • DFP/DFO: 80%

Galanello 2006

  • DFP assessed by pill counts, diary cards and an electronic cap that recorded the time and date of each opening of the tablet container

  • DFO assessed by diary cards, weekly physical examination of infusion sites, and by the Crono™ infusion pump that recorded the number of completed infusions

  • DFP/DFO: DFO: 96.1 ±5.0 (29 participants)

  • DFP compliance was not reported

  • DFO: 95.7 ± 5.7 (30 participants)

Hassan 2016

  • Records of all trial medications that were dispensed and returned

  • Parents were instructed to contact the investigator if the participant were unable to take the trial drug as prescribed

  • All participants compliant with prescribed doses

  • No discontinuation of drugs or dropout of follow‐up occurred

Maggio 2009

  • Counting the pills in each returned bag of DFP

  • Assessing the number of infusions of DFO registered on the electronic pump

  • DFP–DFO group: DFP: 92.7% (SD ± 15.2%; range 37–100%): DFO: 70.6% (SD ± 24.1%; range 25–100%)

  • DFP alone participants: 93.6% (SD ± 9.7%; range 56–100%)

Mourad 2003

  • Number of vials of DFX used

  • Number of tablets of DFO used

  • DFO/DFX group: compliance was excellent (arbitrarily defined as taking > 90% of the recommended doses) in 10 participants and good (75% to 90% of recommended doses) in 1 participant

  • DFX alone group: compliance was considered to be excellent in 11 patients and good in 3 participants

Olivieri 1997

  • Per cent of doses administered: number of doses of the iron chelator taken, out of number prescribed

  • DFP measured with computerised bottles

  • DFO measured using ambulatory pumps

  • Measured for a minimum of 3 months

  • DFP: 94.9% ± 1.1%

  • DFO: 71.6% ± 3.7%

Pennell 2006

  • DFP: measured using the Medication Event Monitoring System device calculated as the percent of openings with an interval longer than 4 hours recorded, divided by number of doses prescribed

  • DFO: calculated as the percentage of completed infusions, as determined by the Crono pumps, divided by the number of infusions prescribed

  • DFP: 94% ± 5.3%

  • DFO: 93% ± 9.7%

Pennell 2014

  • Not stated how adherence was measured

  • DFX: 99.0% ± 3.5%

  • DFO: 100.4% ± 10.9%

Taher 2017

  • Assessed by relative consumed tablet count

  • DT: 85.3% (95% CI: 81.1, 89.5)

  • FCT: 92.9% (95% CI: 88.8, 97.0)

Tanner 2007

  • DFO: calculated as the percentage of completed infusions, as determined by the Crono pumps, divided by the number of infusions prescribed

  • DFP/placebo: pill counting at the bimonthly visits

  • DFO/placebo: DFO: 91.4 ± 2.7%; placebo: 89.8 ± 7.2%;

  • DFO/DFP: DFO: 92.6 ± 2.7%; DFP: 82.4 ± 18.1%

Vichinsky 2007

  • DFX: counting the number of tablets returned in bottles at each visit

  • DFO: counting the numbers of vials returned at each visit

  • Ratios of the administered to intended doses of therapy were high (1.16 for DFX and 0.97 for DFO), indicating high adherence to the prescribed treatment regimens

DFO: deferoxamine
DFP: deferiprone
DFX: deferasirox
DT: dispersible tablet
FCT: film‐coated tablet
SD: standard deviation
SF: serum ferritin

Figures and Tables -
Table 1. Adherence Measurement and Results Table
Comparison 1. DFP versus DFO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Adherence to iron chelation therapy (%, SD) Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Subtotals only

2 SAEs (from therapy, disease, non‐adherence) Show forest plot

1

Risk Ratio (M‐H, Random, 99% CI)

Totals not selected

2.1 Agranulocytosis

1

Risk Ratio (M‐H, Random, 99% CI)

0.0 [0.0, 0.0]

3 All‐cause mortality Show forest plot

1

Risk Ratio (IV, Random, 95% CI)

Totals not selected

4 Iron overload: defined as proportion of participants with serum ferritin ≥ 800 (µg/L) Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

5 Organ damage Show forest plot

1

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

5.1 Liver damage

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

6 Other AEs related to iron chelation Show forest plot

3

Risk Ratio (IV, Random, 99% CI)

Subtotals only

6.1 Risk of leukopenia, neutropenia and/or agranulocytosis

3

192

Risk Ratio (IV, Random, 99% CI)

3.94 [0.44, 35.50]

6.2 Risk of pain or swelling in joints

3

192

Risk Ratio (IV, Random, 99% CI)

3.38 [0.54, 21.31]

6.3 Risk of nausea/vomiting

2

132

Risk Ratio (IV, Random, 99% CI)

13.68 [0.99, 188.88]

6.4 Risk of increased liver transaminase

1

44

Risk Ratio (IV, Random, 99% CI)

1.10 [0.03, 38.47]

6.5 Local reactions at infusion site

1

88

Risk Ratio (IV, Random, 99% CI)

0.17 [0.00, 9.12]

Figures and Tables -
Comparison 1. DFP versus DFO
Comparison 2. DFX versus DFO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Adherence to iron chelation therapy (%, SD) Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

2 SAEs Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

2.1 Thalassaemia‐related SAEs

2

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

2.2 SCD‐related SAE ‐ painful crisis

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

2.3 SCD‐related SAEs ‐ other SCD‐related SAEs

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

3 All‐cause mortality (thalassaemia) Show forest plot

2

240

Risk Ratio (IV, Random, 95% CI)

0.96 [0.06, 15.06]

4 Proportion of participants with iron overload (thalassaemia) Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

4.1 Iron overload defined by ferritin 1500 (µg/l) or higher (Thalassaemia)

1

60

Risk Ratio (M‐H, Random, 95% CI)

1.18 [0.63, 2.20]

4.2 Proportion with severe iron overload (LIC at least 15 mg/Fe/g dw)

1

172

Risk Ratio (M‐H, Random, 95% CI)

1.00 [0.83, 1.20]

4.3 Myocardial T2* < 10ms

1

172

Risk Ratio (M‐H, Random, 95% CI)

1.10 [0.72, 1.70]

5 Other AEs related to iron chelation ‐ (thalassaemia) Show forest plot

2

Risk Ratio (IV, Random, 95% CI)

Subtotals only

5.1 Total chelation‐related AE

1

187

Risk Ratio (IV, Random, 95% CI)

1.15 [0.76, 1.73]

5.2 Gastrointestinal upset

1

60

Risk Ratio (IV, Random, 95% CI)

3.0 [0.66, 13.69]

5.3 Rash

2

247

Risk Ratio (IV, Random, 95% CI)

3.05 [0.98, 9.47]

5.4 Risk of increased blood creatinine

1

187

Risk Ratio (IV, Random, 95% CI)

3.79 [0.83, 17.38]

5.5 Risk of proteinuria

1

187

Risk Ratio (IV, Random, 95% CI)

2.21 [0.59, 8.29]

5.6 Risk of increased ALT

1

187

Risk Ratio (IV, Random, 95% CI)

5.69 [0.70, 46.33]

5.7 Risk of increased AST

1

187

Risk Ratio (IV, Random, 95% CI)

5.69 [0.70, 46.33]

5.8 Risk of diarrhoea

1

187

Risk Ratio (IV, Random, 95% CI)

5.69 [0.70, 46.33]

5.9 Risk of vomiting

1

187

Risk Ratio (IV, Random, 95% CI)

6.64 [0.35, 126.78]

6 Total AEs (thalassaemia) Show forest plot

1

Risk Ratio (IV, Random, 95% CI)

Totals not selected

7 Other AEs related to iron chelation (SCD) Show forest plot

1

Risk Ratio (M‐H, Random, 99% CI)

Subtotals only

7.1 Risk of increased ALT

1

195

Risk Ratio (M‐H, Random, 99% CI)

5.29 [0.12, 232.98]

7.2 incidence of abdominal pain

1

195

Risk Ratio (M‐H, Random, 99% CI)

1.91 [0.80, 4.58]

7.3 Risk of pain or swelling in joints

1

195

Risk Ratio (M‐H, Random, 99% CI)

1.06 [0.41, 2.76]

7.4 Risk of diarrhoea

1

195

Risk Ratio (M‐H, Random, 99% CI)

4.14 [0.90, 18.92]

7.5 Nausea/vomiting

1

195

Risk Ratio (M‐H, Random, 99% CI)

1.63 [0.90, 2.94]

Figures and Tables -
Comparison 2. DFX versus DFO
Comparison 3. DFX film‐coated tablet versus DFX dispersible tablet

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Adherence to iron chelation therapy Show forest plot

1

173

Risk Ratio (M‐H, Random, 95% CI)

1.10 [0.99, 1.22]

2 Incidence of SAEs Show forest plot

1

173

Risk Ratio (IV, Random, 95% CI)

1.22 [0.62, 2.37]

3 All‐cause mortality Show forest plot

1

173

Risk Ratio (M‐H, Random, 95% CI)

2.97 [0.12, 71.81]

4 Incidence of organ damage (renal event) Show forest plot

1

173

Risk Ratio (IV, Random, 95% CI)

1.25 [0.83, 1.91]

5 Other AEs related to iron chelation Show forest plot

1

Risk Ratio (IV, Random, 99% CI)

Subtotals only

5.1 Total chelation‐related AEs

1

173

Risk Ratio (IV, Random, 99% CI)

0.75 [0.52, 1.08]

5.2 Risk of diarrhoea

1

173

Risk Ratio (IV, Random, 99% CI)

0.70 [0.29, 1.70]

5.3 Increased urine protein/urine creatinine ratio

1

173

Risk Ratio (IV, Random, 99% CI)

1.65 [0.60, 4.54]

5.4 incidence of abdominal pain

1

173

Risk Ratio (IV, Random, 99% CI)

0.49 [0.16, 1.52]

5.5 Incidence of nausea

1

173

Risk Ratio (IV, Random, 99% CI)

0.72 [0.23, 2.23]

5.6 Incidence of vomiting

1

173

Risk Ratio (IV, Random, 99% CI)

0.28 [0.07, 1.15]

Figures and Tables -
Comparison 3. DFX film‐coated tablet versus DFX dispersible tablet
Comparison 4. DFP and DFO versus DFP

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of SAEs Show forest plot

1

213

Risk Ratio (M‐H, Random, 95% CI)

0.15 [0.01, 2.81]

2 All‐cause mortality Show forest plot

2

237

Risk Ratio (IV, Random, 95% CI)

0.77 [0.18, 3.35]

3 Incidence of chelation therapy‐related AEs Show forest plot

3

Risk Ratio (IV, Random, 99% CI)

Subtotals only

3.1 Risk of leukopenia, neutropenia and/or agranulocytosis

3

280

Risk Ratio (IV, Random, 99% CI)

1.15 [0.50, 2.62]

3.2 Risk of pain or swelling in joints

2

256

Risk Ratio (IV, Random, 99% CI)

0.76 [0.31, 1.91]

3.3 Risk of gastrointestinal disturbances

1

213

Risk Ratio (IV, Random, 99% CI)

0.45 [0.15, 1.37]

3.4 Risk of increased liver transaminase

2

256

Risk Ratio (IV, Random, 99% CI)

1.02 [0.52, 1.98]

3.5 Nausea/vomiting

1

43

Risk Ratio (IV, Random, 99% CI)

0.55 [0.13, 2.23]

Figures and Tables -
Comparison 4. DFP and DFO versus DFP
Comparison 5. DFP and DFO versus DFO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Other AEs related to iron chelation Show forest plot

4

Risk Ratio (IV, Random, 99% CI)

Subtotals only

1.1 Risk of leukopenia, neutropenia and/or agranulocytosis

3

169

Risk Ratio (IV, Random, 99% CI)

1.18 [0.09, 15.37]

1.2 Risk of pain or swelling in joints

3

135

Risk Ratio (IV, Random, 99% CI)

2.39 [0.18, 32.31]

1.3 Risk of increased liver transaminase

2

104

Risk Ratio (IV, Random, 99% CI)

3.46 [0.45, 26.62]

1.4 Nausea/vomiting

4

194

Risk Ratio (IV, Random, 99% CI)

3.81 [0.84, 17.36]

1.5 Local reactions at infusion site

2

90

Risk Ratio (IV, Random, 99% CI)

0.18 [0.01, 3.56]

Figures and Tables -
Comparison 5. DFP and DFO versus DFO
Comparison 6. DFP/DFX versus DFP/DFO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Adherence to iron chelation therapy rates Show forest plot

1

96

Risk Ratio (IV, Random, 95% CI)

0.84 [0.72, 0.99]

2 Incidence of SAE Show forest plot

1

96

Risk Ratio (M‐H, Random, 95% CI)

1.0 [0.06, 15.53]

3 All‐cause mortality Show forest plot

1

Risk Ratio (IV, Random, 95% CI)

Totals not selected

4 Organ damage (serum creatinine (≥33%) above baseline in 2 consecutive occasions) Show forest plot

1

96

Risk Ratio (M‐H, Random, 99% CI)

3.0 [0.16, 56.04]

5 Other AEs related to iron chelation Show forest plot

1

Risk Ratio (IV, Random, 99% CI)

Subtotals only

5.1 one year (study end)

1

96

Risk Ratio (IV, Random, 99% CI)

1.08 [0.68, 1.71]

5.2 Risk of leukopenia, neutropenia and/or agranulocytosis

1

96

Risk Ratio (IV, Random, 99% CI)

1.67 [0.27, 10.14]

5.3 Risk of pain or swelling in joints

1

96

Risk Ratio (IV, Random, 99% CI)

0.89 [0.29, 2.77]

5.4 Gastrointestinal problems

1

96

Risk Ratio (IV, Random, 99% CI)

0.6 [0.18, 2.04]

5.5 ALT (increase ≥3 folds)

1

96

Risk Ratio (IV, Random, 99% CI)

1.33 [0.20, 8.88]

5.6 Skin rash

1

96

Risk Ratio (IV, Random, 99% CI)

5.0 [0.10, 261.34]

Figures and Tables -
Comparison 6. DFP/DFX versus DFP/DFO